Quick Answer
NovoCure Ltd reported Research And Development Expense of $224.54 million for the year ending 2025.
- NovoCure Ltd showed an increase of +7.1% in Research And Development Expense from 2024 to 2025.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), NovoCure Ltd's Research And Development Expense has grown by 545.3%.
- Historical annual values: Fiscal year 2025: $224.54 million | Fiscal year 2024: $209.65 million | Fiscal year 2023: $223.06 million | Fiscal year 2022: $206.09 million | Fiscal year 2021: $201.30 million | Fiscal year 2020: $132.01 million | Fiscal year 2019: $79.00 million | Fiscal year 2018: $50.57 million | Fiscal year 2017: $38.10 million | Fiscal year 2016: $41.47 million | Fiscal year 2015: $43.75 million | Fiscal year 2014: $40.38 million | Fiscal year 2013: $34.80 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: